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Background: Beyond lung cancer, screening CT contains additional information on other smoking related diseases
(e.g. chronic obstructive pulmonary disease, COPD). Since pulmonary function testing is not regularly incorporated
in lung cancer screening, imaging biomarkers for COPD are likely to provide important surrogate measures for
disease evaluation. Therefore, this study aims to determine the independent diagnostic value of CT emphysema,
CT air trapping and CT bronchial wall thickness for COPD in low-dose screening CT scans.
Methods: Prebronchodilator spirometry and volumetric inspiratory and expiratory chest CT were obtained on the
same day in 1140 male lung cancer screening participants. Emphysema, air trapping and bronchial wall thickness
were automatically quantified in the CT scans. Logistic regression analysis was performed to derivate a model to
diagnose COPD. The model was internally validated using bootstrapping techniques.
Results: Each of the three CT biomarkers independently contributed diagnostic value for COPD, additional to age,
body mass index, smoking history and smoking status. The diagnostic model that included all three CT biomarkers
had a sensitivity and specificity of 73.2% and 88.%, respectively. The positive and negative predictive value were
80.2% and 84.2%, respectively. Of all participants, 82.8% was assigned the correct status. The C-statistic was 0.87,
and the Net Reclassification Index compared to a model without any CT biomarkers was 44.4%. However, the
added value of the expiratory CT data was limited, with an increase in Net Reclassification Index of 4.5% compared
to a model with only inspiratory CT data.
Conclusion: Quantitatively assessed CT emphysema, air trapping and bronchial wall thickness each contain
independent diagnostic information for COPD, and these imaging biomarkers might prove useful in the absence of
lung function testing and may influence lung cancer screening strategy. Inspiratory CT biomarkers alone may be
sufficient to identify patients with COPD in lung cancer screening setting.
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Computed Tomography (CT)-based lung cancer screen-
ing has gained much interest after the National Lung
Screening Trial (NLST) reported a 20% lung cancer
mortality reduction in the CT arm compared to the
chest radiography arm of the screening trial [1]. Al-
though implementation and cost-effectiveness is cur-
rently debated, screening has already started after the
release of guidelines by two major organizations in the
U.S. [2,3]. Lung cancer screening CT scans enable the
evaluation of other smoking-induced diseases besides
lung cancer, such as chronic obstructive pulmonary
disease (COPD), which accounts for significant morbidi-
ty and mortality and is also associated with an increased
risk for lung cancer. Additional diagnosis of COPD
might potentially be useful in the optimization of bene-
fits and cost-effectiveness of CT-based screening in
heavy smokers, and may also aid in the identification of
the optimal target population for lung cancer screening
[4] and personalization of lung cancer screening inter-
vals. However, the opportunity of additional disease
evaluation is not yet widely acknowledged [5].
Since lung function testing is not regularly incorporated
in lung cancer screening, quantitative imaging biomarkers
for COPD are likely to provide important surrogate mea-
surements for disease evaluation. Moreover, computerized
quantitative analysis is diagnostically superior to visual
scores by human observers [6]. It has recently been shown
that automated quantitative analysis of screening CT
images may be used to additionally identify COPD among
screening participants [7]. In that study, CT emphysema
and CT air trapping, together with age, body mass index,
smoking status and packyears smoked, provided good
accuracy in the identification of COPD. To quantify the
extent of air trapping, expiratory CT was added to the
lung cancer screening protocol [7].
Software technology now allows for fully automatic
analysis of bronchial wall thickness in inspiratory CT
[8,9]. Bronchial dimensions of the larger airways on CT
have been shown to correlate well with those of the
small airways measured by pathology [10], which may
suggest that both reflect small airways disease. Another
option is that large airway wall thickening is a separate
marker of airway disease and visualizes the chronic
bronchitis component of COPD [11,12]. Therefore,
quantification of bronchial wall thickness may be able to
either replace the CT air trapping measurements (and
hence the need for additional expiratory imaging), or
may add independent diagnostic value for COPD and
therewith improve the diagnostic performance of CT.
The objective of this study is to determine the indepen-
dent diagnostic value of CT emphysema, CT air trapping
and CT bronchial wall thickness in the identification of
COPD in low-dose lung cancer screening CT.Materials and methods
This study was performed as a side-study of the Dutch
and Belgian lung cancer screening trial (NELSON-trial,
ISRCTN 63545820) [13]. The study was approved by
both the Dutch Ministry of Health and the local ethical
review board of the University Medical Center Utrecht.
Each participant provided written informed consent.
Subjects
The selection of the study population has been described
in detail elsewhere [7]. In summary, we included 1140
male subjects with a paired inspiratory and expiratory
CT obtained on the same day between July 2007 and
September 2008. The included study population was a
subsample of the total lung cancer screening population.
The subsample did not differ significantly from the total
population of subjects screened for lung cancer, as pre-
viously reported [7]. Participants included in the lung
cancer screening trial were current and former (<10 year)
heavy smokers with a smoking history of at least 16.5
packyears, and were at baseline between 50 and 75 years
of age. All participants weighted less than 140 kg and
were physically fit enough to undergo surgery. Partici-
pants provided self-reported presence of respiratory
symptoms. Participants were asked to indicate whether
cough, sputum production, dyspnea and wheezing were
present for at least three months a year. A symptomatic
status was assigned when presence of at least 1 of the
symptoms was reported. Otherwise, a participant was
assigned an asymptomatic status.
Pulmonary function testing
Prebronchodilator spirometry was performed using ZAN
equipment (ZAN Messgeräte GmbH, Germany), accor-
ding to European Respiratory Society and American
Thoracic Society guidelines [14,15]. Forced expiratory
volume in one second (FEV1) was expressed as percen-
tage predicted. Forced vital capacity was expressed as
percentage. We defined COPD as FEV1/FVC below 70%,
with a classification into mild (FEV1 ≥ 80%), moderate
(80% > FEV1 ≥ 50%) and severe (50% > FEV1 ≥ 30%).
Computed tomography
All subjects received paired inspiratory and expiratory
CT, obtained with 16 × 0.75 mm collimation (Brilliance
16P; Philips Medical Systems). Data was acquired accor-
ding to the low-dose protocol of the lung cancer scree-
ning trial; 120 kVp (≤80 kg) or 140 kVp (>80 kg) both at
30 mAs for the inspiratory CT, and 90 kVP (≤80 kg) or
120 kVp (>80 kg) both at 20 mAs for the expiratory CT.
The estimated effective dose was at maximum 1.4
millisievert (mSv) for the inspiratory acquisition, and at
maximum 0.65 mSv for the expiratory acquisition. CT im-
ages were reconstructed from lung bases to apices with
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smooth reconstruction algorithm (B-filter, Philips).
Quantitative analysis of emphysema and air trapping
The lungs were automatically segmented from the chest
wall, mediastinum, airways, vessels and diaphragm using
dedicated software [16]. A noise reduction filter was ap-
plied to decrease the influence of noise in the low-dose
CT images [17]. In both the inspiratory and expiratory
images, the attenuation of each voxel in the segmented
lung volume was determined and distributed in a density
histogram. From these histograms, CT emphysema and
CT air trapping were calculated; CT emphysema was de-
fined as the percentage of voxels below −950 HounsfieldA
C
E
Figure 1 Illustration of the lung segmentation process and calculatio
image; B = Axial expiratory CT image; C and D = Overlay showing the lung
slice. The trachea and main bronchi are shown in blue; E = Overlay showin
showing the attenuation histograms of both the inspiratory and expiratory
below −950 HU. CT air trapping is calculated as the ratio of the expiratoryUnit (HU) [18]; IN−950. CT air trapping was defined as
the ratio of expiratory to inspiratory mean lung density
[19,20]; E/I-ratioMLD. We previously found this to be the
most robust measure of air trapping that correlated most
closely with lung function [21-23]. Figure 1 illustrates
the quantitative assessment of CT emphysema and CT
air trapping.
Quantitative analysis of bronchial dimensions
The lumen was automatically segmented based on auto-
matic trachea detection and a tree-oriented region grow-
ing with multiple optimal thresholds, and converted to a
centerline model [8]. Across all centerlines, bronchial
cross-sections were defined perpendicular to the localB
D
F
n of CT emphysema and CT air trapping. A = Axial inspiratory CT
segmentation of the right (turquoise) and left (green) lung in an axial
g the lung segmentation in a coronal inspiratory CT image; F = Graph
CT. CT emphysema is calculated as the percentage of voxels
to inspiratory mean lung density.
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the inner and outer bronchial wall boundaries were
determined in each of these cross-sections, based on an
intensity-integration-based analysis of 72 rays pointing
outwards radially from the centerpoint [9]. Cross-sections
obtained from the trachea, main bronchi, branching re-
gions as well as cross-sections where the bronchial wall
segmentation failed were automatically excluded from
further analysis. Using all remaining cross-sections, the
regression line of the square root of the wall area versus
the lumen perimeter was calculated. The square root of
wall area for a theoretical bronchus with 10 mm lumen
perimeter (Pi10) was calculated for each subject, which
was used as the parameter for bronchial wall thickness
[24,25]. Figure 2 illustrates the bronchial segmentation
process and the quantitative assessment of CT bronchial
wall thickness.Figure 2 Illustration of the bronchial segmentation process and the c
figure shows the bronchial tree segmentation of the right and left lung, bo
of bronchial cross-sections obtained perpendicular to the bronchial lumen
outer (orange) bronchial wall boundaries are shown; solid lines represent o
boundaries. From the observed bronchial wall boundaries the wall area is c
regression line (dashed line) through the bronchial measurements, from w
10 mm lumen perimeter (i.e. Pi10) was calculated (dotted lines).To check the bronchial segmentation process in each
case, the 3D bronchial tree segmentation, a random
selection of about 90 bronchial cross-sections and the
plotted regression line were presented to an independent
observer. After carefully reviewing the segmentation
results cases with major errors in the bronchial tree seg-
mentation (N = 22) or where segmentation failed (N = 6)
were excluded. No manual corrections were performed.Statistical analysis
To obtain normal distribution, transformation using the
natural logarithm was applied on the CT emphysema
measure (logIN−950). The other variables did not have to
be transformed. Missing values were imputed using mul-
tiple imputation technique; quantitative bronchial wall
measurements were missing in 28 cases and respiratoryalculation of CT bronchial wall thickness. The upper part of the
th separately and combined. The lower part shows a random selection
center line. In these bronchial cross-sections, the inner (yellow) and
bserved boundaries whereas dashed lines represent interpolated
alculated. The line graph shows a schematic representation of a
hich the square root of wall area for a theoretical bronchial with
Table 1 Study population characteristics
Characteristic Mean ± SD or Number (%)
N = 1140
Age, years 62.5 ± 5.2
Body mass index, kg/m2 27.1 ± 3.6
Smoking status
Current smoker 609 (53.4)
Former smokers 531 (46.6)
Packyears * 38 (28 – 49)
COPD † 437 (38.3)
Mild disease ‡ 277 (63.4)
Moderate disease § 135 (30.9)
Severe disease ll 25 (5.7)
* Data presented as median (25th – 75th percentile); † COPD is defined as
FEV1/FVC < 70%;
‡ FEV1(% predicted) ≥80%;
§ 80% > FEV1(% predicted) ≥ 50%;
ll 50% > FEV1 (% predicted) ≥ 30%;
FEV1 = forced expiratory volume in one second; FEV1/FVC = ratio of forced
expiratory volume in one second over forced vital capacity.
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other variables with missing values.
Various multivariate models were developed using
logistic regression analysis with COPD as outcome vari-
able. The modeling started with a baseline model inclu-
ding only demographic variables (i.e. age, body mass
index, smoking history and smoking status) as associated
variables. Subsequently, quantitative CT emphysema,
CT air trapping, and CT bronchial wall thickness were
added to the analysis in a stepwise fashion. This resulted
in a total of eight different models: 1) demographic vari-
ables only; 2) demographic variables + CT emphysema;
3) demographic variables + CT air trapping; 4) demogra-
phic variables + CT bronchial wall thickness; 5) demo-
graphic variables + CT bronchial wall thickness + CT air
trapping; 6) demographic variables + CT emphysema +
CT air trapping; 7) demographic variables + CT emphy-
sema + CT bronchial wall thickness; 8) demographic
variables + CT emphysema + CT bronchial wall thick-
ness + CT air trapping.
Internal validation was performed for each model by
assessing the overoptimism, using bootstrap resampling
with 500 iterations [26,27], and subsequent shrinkage of
the initial coefficients by the estimated degree of over-
optimism [28]. Calibration (i.e. the agreement between
the predicted and observed values) of the shrunk models
was assessed visually using the calibration plots. Dis-
crimination (i.e. the ability of a model to differentiate
between subjects with and without COPD) was assessed
by calculation of the area under the receiver operating
characteristic (ROC) curve (i.e. C-statistic). The point of
optimal accuracy was defined as the highest number of
true positive plus true negative cases. For this cut-off
value, sensitivity and specificity was calculated for each
model. Using the Net Reclassification Index (NRI) [29],
all eight models were compared to each other to deter-
mine the added value of each quantitative marker. The
NRI assesses the added usefulness of a marker by show-
ing the increase in correctly categorized cases (i.e. the
shift from false negative to true positive and from false
positive to true negative). In addition to the primary
analysis in the total study population, we also applied
each model separately in the subgroups of symptomatic
and asymptomatic subjects.
A p-value lower than 0.05 was considered to represent
a statistically significant difference. Analysis were perfor-
med using R-statistical program (v.2.13.1) using regres-
sion modeling strategies v.3.3-0 and ROCR v.1.0-4 [30].
Values are presented as mean ± SD, unless indicated
otherwise.
Results
Details of the 1140 male lung cancer screening trial par-
ticipants included in this study are presented in Table 1.Quantitative CT analysis
Segmented lung volumes were 6.79 ± 1.13 liter in
inspiratory CT and 3.71 ± 0.90 liter in expiratory CT.
The quantified amount of CT emphysema showed a me-
dian (P25 – P75) value of 0.75 (0.40 – 1.46)%. For CT
air trapping this was 0.84 (0.80 – 0.88). On average
1280 ± 403 (range 260 – 3536) bronchial cross-sections
throughout the lung were obtained per subject. The Pi10
for all participants was 2.41 ± 0.51 mm.
Diagnostic performance of the multivariate models
The baseline model including only demographic vari-
ables showed a C-statistic of 0.652. Separately adding
the three quantitative CT biomarkers significantly im-
proved the model. The model with CT emphysema
showed a C-statistic of 0.784 and an NRI of 22.2%. The
model with CT bronchial wall thickness showed a C-
statistic of 0.755 and an NRI of 14.7%. The model with
CT air trapping showed a C-statistic of 0.773 and an
NRI of 24.7%. Details on the reclassification can be eva-
luated based on the shift in false and true positives and
false and true negatives, these data are presented in
Table 2.
When a combination of two CT biomarkers was added
to the baseline model, diagnostic performance improved
even further. Combinations of emphysema and air trap-
ping, emphysema and bronchial wall thickening, or air
trapping and bronchial wall thickening showed a C-
statistic of 0.834, 0.861 and 0.801, respectively. The NRI
compared to the baseline model was 32.4%, 39.9% and
24.8%, respectively.
Ultimately, all three quantitative CT biomarkers were
added to the baseline model. In this full model all
biomarkers showed independent diagnostic value for
Table 2 Performance measures for the various multivariate models to identify COPD
Model TP FN TN FP ACC SENS SPEC PPV NPV
(n) (n) (n) (n) (%) (%) (%) (%) (%)
1 Baseline model * 125 312 630 73 66.2 28.6 89.6 63.1 66.9
2 + CT-BWT 185 252 637 66 72.1 42.3 90.6 73.7 71.7
3 + CT air trapping 317 120 495 208 71.2 72.5 70.4 60.4 80.5
4 + CT emphysema 229 208 619 84 74.4 52.4 88.1 73.2 74.8
5 + CT-BWT 237 200 624 79 75.5 54.2 88.8 75.0 75.7
+ CT air trapping
6 + CT emphysema 274 163 618 85 78.2 62.7 87.9 76.3 79.1
+ CT air trapping
7 + CT emphysema 309 128 610 93 80.6 70.7 86.8 76.9 82.7
+ CT-BWT
8 + CT emphysema 320 117 624 79 82.8 73.2 88.8 80.2 84.2
+ CT-BWT
+ CT air trapping
* Model including age, body mass index, smoking status and packyears of smoking history; TP = true positive; FN = false negative; TN = true negative; FP = false
positive; ACC = Accuracy; SENS = Sensitivity; SPEC = Specificity; PPV = Positive predicted value; NPV = Negative predictive value; CT-BWT = Quantitatively assessed
bronchial wall thickness.
Table 3 Discrimination of the various multivariate models
in the identification of COPD in subgroups of
asymptomatic and symptomatic subjects
Model C-index (95% CI)
Asymptomatics Symptomatics
1 Baseline model * 0.674 (0.625 -0.722) 0.634 (0.589 - 0.679)
2 + CT-BWT 0.739 (0.695 - 0.783) 0.764 (0.725 - 0.803)
3 + CT air trapping 0.737 (0.693 - 0.780) 0.794 (0.759 - 0.829)
4 + CT emphysema 0.753 (0.707 – 0.800) 0.806 (0.771 - 0.841)
5 + CT-BWT 0.771 (0.730 – 0.813) 0.821 (0.788 – 0.855)
+ CT air trapping
6 + CT emphysema 0.782 (0.740 - 0.824) 0.872 (0.844 - 0.899)
+ CT air trapping
7 + CT emphysema 0.828 (0.790 – 0.866) 0.886 (0.859 - 0.912)
+ CT-BWT
8 + CT emphysema 0.832 (0.795 – 0.869) 0.905 (0.881 - 0.929)
+ CT-BWT
+ CT air trapping
* Model including age, body mass index, smoking status and packyears of
smoking history; 95% CI = 95th percentile confidence interval; CT-BWT =
Quantitatively assessed bronchial wall thickness.
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jects was reclassified into the correct category compared
to the model with only inspiratory CT biomarkers. This
full model identified 320 of all 437 COPD cases at the
cost of 79 false positives, yielding a sensitivity of 73.2%
and a specificity of 88.8%. The full model automatically
assigned 82.8% of the subjects the correct status. The
full model had a C-statistic of 0.873, and compared to
the baseline model the full model reclassified 44.4% of
the subjects. In the symptomatic subjects the C-statistic
of this full model increased to 0.905 [Table 3].
Discussion
This study shows that CT emphysema, CT air trapping
and CT bronchial wall thickness, automatically assessed
on low-dose lung cancer screening CT images, all have
independent diagnostic value for COPD. The best per-
formance measures were shown by the model that
included all three quantitative CT biomarkers. This full
model yielded a very good diagnostic performance and
assigned the correct status the vast majority of the
screening participants. Using the full model almost
three-quarter of the COPD subjects in our population
were automatically identified, with a low false-positive
rate. However, the additional diagnostic value of expira-
tory CT was limited, and performance measures remained
sufficient when expiratory CT was not included.
Our results lead to several considerations. Firstly,
although the concept of additional COPD detection has
yet received limited attention and early diagnosis of
COPD is subject to debate, the concept of identifyingCOPD as early as possible using screening CT is feasible.
The actual extent of benefits from early diagnosis and
intensified smoking cessation-strategies is yet unknown,
however, it has been shown that early smoking cessation
lowers disease progression and decreases COPD-related
morbidity and mortality [31,32]. Moreover, in the setting
of lung cancer screening there is also a second rationale
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ses the risk of developing lung cancer and therefore may
aid in risk assessment and personalization of the screen-
ing strategy [4]. Since lung function testing is generally
not included in lung cancer screening, other measure-
ments might be needed to allow for COPD evaluation.
Imaging biomarkers as presented in this study may thus
prove important surrogate measures in lung cancer
screening setting. Notwithstanding, it should be empha-
sized that the approach of using automated identification
of COPD in screening CT cannot yet be widely imple-
mented at this moment as it needs to be externally
validated and quantitative CT analyses need further
standardization to allow inter-technique and inter-site
comparison [33].
Secondly, our results show that inspiratory CT bron-
chial wall thickness might usefully replace the expiratory
CT air trapping measurements. This is specifically inter-
esting given that expiratory acquisitions are generally
not performed in other screening trials, and might not
be performed when lung cancer screening is actually
implemented. The present study shows that the sen-
sitivity and specificity of the diagnostic model remained
acceptable when expiratory air trapping was not inclu-
ded into the model, implying that inspiratory CT bio-
markers alone are valuable in identifying patients with
COPD in early stages in routine lung cancer screening
setting. Although addition of the expiratory CT data did
reclassify a further 4.5% of subjects, this effect is limited
for diagnostic purposes and may not justify obtaining an
expiratory CT scan in each screening participant.
Our study has several potential limitations. Firstly, the
generalizability of our study may be limited given that
our study population comprises only males. Few women
are included in the lung cancer screening trial, since
there are few women in the Dutch population with accu-
mulated long-term smoking histories [13]. Also, differ-
ences in CT protocols (e.g. CT equipment, dose settings,
reconstruction algorithm) may influence absolute values
obtained from quantitative image analysis. Although we
believe it is highly unlikely that such differences could
lead to contradicting findings when applied in another
study, close attention should always be paid to technical
parameters when comparing quantitative results. Sec-
ondly, while the official definition of COPD is based on
post-bronchodilator spirometry, spirometry in the lung
cancer screening trial was obtained without administra-
tion of a bronchodilator due to time restrictions. This
may lead to some misclassification due to asthma. How-
ever, we do not think this is an important confounder
given that the prevalence of asthma in a population of
heavy smokers is generally very low. In the Netherlands
asthma is present in about 2% of all males between 50
and 75 years of age [34].Conclusion
In the absence of lung function testing quantitative CT
biomarkers provide useful surrogate measures for COPD
evaluation, which may in the future influence screening
strategy and enhance screening benefits and cost-
effectiveness. The present study shows that quantita-
tively assessed CT emphysema, CT air trapping and CT
bronchial wall thickness each contain independent diag-
nostic information for COPD, and represent independ-
ent imaging biomarkers. As the added diagnostic value
of expiratory CT air trapping is limited, inspiratory CT
biomarkers alone may be sufficient to identify subjects
with COPD in lung cancer screening setting.
Competing interests
Conflicts of interest for the present study: EM van Rikxoort received a grant
Netherlands Organisation for Scientific Research (NWO). P Zanen received a
grant (EU FP7 grant COPACETIC HEALTH-2007-2.4.5-6).
Conflicts of interest outside the present study: JWJ Lammers received an
institutional grant (EU 201379 Copacetic). HJ de Koning received money for
Member Advisory Board Roche Diagnostics. M Prokop received institutional
grants from Philips and Toshiba Medical Systems. He also received money
for lectures or travel expenses from Bracco, CME Science, ESOR, Bayer –
Schering, Philips and Toshiba Medical Systems.
Authors’ contributions
Conception and design of the study was performed by MO RV HJK CA MP
JWJL WPThMM BG EMR and PAJ. Data collection was performed by OMM
MS II PZ FAAM BG and EMR. Analysis and interpretation of the data was
performed by OMM MS CFB MJG EMR and PAJ. The manuscript drafts were
written by OMM MS EMR and PAJ. The manuscript was critically revised by
CFB MJG II MO RV HJK CA MP JWJL PZ FAAM WPThMM and BG. All authors
read and approved the final manuscript.
Acknowledgements
The NELSON-trial was supported by the Netherlands Organisation for Health
Research and Development; Dutch Cancer Society Koningin Wilhelmina
Fonds; Stichting Centraal Fonds Reserves van Voormalig Vrijwillige
Ziekenfondsverzekeringen; Siemens Germany; Roche Diagnostics; Rotterdam
Oncologic Thoracic Steering Committee; and the G.Ph. Verhagen Trust,
Flemish League Against Cancer, Foundation Against Cancer, and Erasmus
Trust Fund.
Author details
1Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA
Utrecht, The Netherlands. 2Fraunhofer MEVIS, Universitätsallee 29, 28359
Bremen, Germany. 3Diagnostic Image Analysis Group, Radiology, Radboud
University Nijmegen Medical Centre, Geert Grooteplein 10, 6525 GA
Nijmegen, The Netherlands. 4Julius Center for Health Sciences and Primary
Care, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA
Utrecht, The Netherlands. 5Image Sciences Institute, University Medical
Center Utrecht, Heidelberglaan 100, 3508GA Utrecht, The Netherlands.
6Radiology, University Medical Center Groningen, Hanzeplein 1, 9700 RB
Groningen, The Netherlands. 7Department of Public Health, Erasmus Medical
Center Rotterdam, Dr. Molewaterplein 50, 3015 CE Rotterdam, The
Netherlands. 8Radiology, Radboud University Nijmegen Medical Centre, Geert
Grooteplein 10, 6525 GA Nijmegen, The Netherlands. 9Pulmonology,
University Medical Center Utrecht, Heidelberglaan 100, 3508 GA Utrecht, The
Netherlands.
Received: 1 March 2013 Accepted: 24 May 2013
Published: 27 May 2013
References
1. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality
with low-dose computed tomographic screening. N Engl J Med 2011,
365(5):395–409.
Mets et al. Respiratory Research 2013, 14:59 Page 8 of 8
http://respiratory-research.com/content/14/1/592. Wood DE, Eapen GA, Ettinger DS, et al: Lung cancer screening. J Natl
Compr Canc Netw 2012, 10(2):240–265.
3. American Lung Association: Providing Guidance for Lung Cancer Screening: The
American Lung Association Interim Report on Lung Cancer Screening. 2012.
Available from: [http://www.lung.org/finding-cures/research-news/new-
screening-guidelines/lung-cancer-screening.pdf]. Accessed February 2013.
4. Young RP, Hopkins RJ: Lung cancer risk prediction to select smokers for
screening CT. Cancer Prev Res 2012, 5(4):697–698.
5. Mets OM, de Jong PA, Prokop M: Computed tomographic screening for
lung cancer: an opportunity to evaluate other diseases. JAMA 2012,
308(14):1433–1434.
6. Mets OM, Smit EJ, Mohamed Hoesein FA, et al: Visual versus automated
evaluation of chest computed tomography for the presence of chronic
obstructive pulmonary disease. PLoS One 2012, 7(7):e42227.
7. Mets OM, Buckens CF, Zanen P, et al: Identification of chronic obstructive
pulmonary disease in lung cancer screening computed tomographic
scans. JAMA 2011, 306(16):1775–1781.
8. van Ginneken B, Baggerman W, van Rikxoort EM: Robust segmentation
and anatomical labeling of the airway tree from thoracic CT scans.
Med Image Comput Comput Assist Interv 2008, 11(Pt 1):219–226.
9. Schmidt M, Kuhnigk JM, Krass S, Owsijewitsch M, Hoop BJ, Peitgen H:
Reproducibility of airway wall thickness measurements. Proceedings of the
SPIE, Medical Imaging 2010, 7624:76240-1–76240-10.
10. Nakano Y, Muro S, Sakai H, et al: Computed tomographic measurements
of airway dimensions and emphysema in smokers. Correlation with lung
function. Am J Respir Crit Care Med 2000, 162(3 Pt 1):1102–1108.
11. Kim V, Han MK, Vance GB, et al: The chronic bronchitic phenotype of
chronic obstructive pulmonary disease: An analysis of the COPDgene
study. Chest 2011, 140(3):626–633.
12. Mair G, Maclay J, Miller JJ, et al: Airway dimensions in COPD: relationships
with clinical variables. Respir Med 2010, 104(11):1683–1690.
13. van Iersel CA, de Koning HJ, Draisma G, et al: Risk-based selection from
the general population in a screening trial: selection criteria, recruitment
and power for the Dutch-Belgian randomised lung cancer multi-slice CT
screening trial (NELSON). Int J Cancer 2007, 120(4):868–874.
14. Miller MR, Crapo R, Hankinson J, et al: General considerations for lung
function testing. Eur Respir J 2005, 26:153–161.
15. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC:
Lung volumes and forced ventilatory flows. Report Working Party
Standardization of Lung Function Tests, European Community for Steel
and Coal. Official Statement of the European Respiratory Society.
Eur Respir J Suppl 1993, 16:5–40.
16. van Rikxoort EM, de Hoop B, Viergever MA, Prokop M, van Ginneken B:
Automatic lung segmentation from thoracic computed tomography
scans using a hybrid approach with error detection. Med Phys 2009,
36:2934–2947.
17. Schilham AM, van Ginneken B, Gietema H, Prokop M: Local noise weighted
filtering for emphysema scoring of low-dose CT images. IEEE Trans Med
Imaging 2006, 25:451–463.
18. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC: Comparison
of computed density and macroscopic morphometry in pulmonary
emphysema. Am J Respir Crit Care Med 1995, 152(2):653–657.
19. O'Donnell RA, Peebles C, Ward JA, et al: Relationship between peripheral
airway dysfunction, airway obstruction, and neutrophilic inflammation in
COPD. Thorax 2004, 59(10):837–842.
20. Mets OM, Murphy K, Zanen P, et al: The Relationship between Lung
Function Impairment and Quantitative Computed Tomography in
Chronic Obstructive Pulmonary Disease. Eur Radiol 2012, 22(1):120–128.
21. Mets OM, Zanen P, Lammers JW, et al: Early Identification of Small Airways
Disease on Lung Cancer Screening CT: Comparison of Current Air
Trapping Measures. Lung 2012, 190(6):629–633.
22. Mets OM, Isgum I, Mol CP, et al: Variation in quantitative CT air
trapping in heavy smokers on repeat CT examinations. Eur Radiol 2012,
22(12):2710–2717.
23. Mets OM, Willemink MJ, de Kort FP, et al: The effect of iterative
reconstruction on computed tomography assessment of emphysema, air
trapping and airway dimensions. Eur Radiol 2012, 22(10):2103–2109.
24. Nakano Y, Wong JC, de Jong PA, et al: The prediction of small airway
dimensions using computed tomography. Am J Respir Crit Care Med 2005,
171(2):142–146.25. Patel BD, Coxson HO, Pillai SG, et al: Airway wall thickening and
emphysema show independent familial aggregation in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2008,
178(5):500–505.
26. Harrell F: Regression modeling strategies with Applications to Linear Models,
Logistic Regression, and Survival Analysis. New York: Springer; 2001.
27. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. London: Chapman &
Hall; 1993.
28. Steyerberg EW: Clinical Prediction Models: A practical approach to
development, validation and updating. New York: Springer; 2009.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the
added predictive ability of a new marker: from area under the ROC
curve to reclassification and beyond. Stat Med 2008, 27(2):157–172.
30. R Development Core Team: R: A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing. Available
from: [http://www.R-project.org/]. Accessed February 2013.
31. Soriano JB, Zielinski J, Price D: Screening for and early detection of
chronic obstructive pulmonary disease. Lancet 2009, 374(9691):721–732.
32. Decramer M, Sibille Y, Bush A, et al: The European Union conference on
chronic respiratory disease: purpose and conclusions. Eur Respir J 2011,
37(4):738–742.
33. Mets OM, de Jong PA, van Ginneken B, Gietema HA, Lammers JWJ:
Quantitative Computed Tomography in COPD: Possibilities and
limitations. Lung 2012, 190(2):133–145.
34. Nationaal Kompas Volksgezondheid [National Public Health Compass]:
Available from: [http://www.nationaalkompas.nl/gezondheid-en-ziekte/
ziekten-en-aandoeningen/ademhalingswegen/astma/omvang].
Accessed February 2013.
doi:10.1186/1465-9921-14-59
Cite this article as: Mets et al.: Diagnosis of chronic obstructive
pulmonary disease in lung cancer screening Computed Tomography
scans: independent contribution of emphysema, air trapping and
bronchial wall thickening. Respiratory Research 2013 14:59.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
